Finance

Lists
Why is GH up ၄.၁၀%?
Dive Deeper
GH:NASDAQ
Guardant Health Inc
၁၆၉.၂၅ US$
+၄.၁၀%
(+၆.၆၆) 1D
အောက် ၂၁, GMT-၄ ၁၁:၃၅:၅၇  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GH...
Open
၁၆၂.၂၉ US$
High
၁၇၀.၅၀ US$
Low
၁၆၂.၀၀ US$
Mkt. cap
ဋေ ၂.၂၇ ထ
Avg. vol.
၁.၇၈ သန်း
Volume
၆.၆၁ သိန်း
52-wk high
၁၉၁.၀၅ US$
52-wk low
၆၆.၅၉ US$
EPS
-၃.၅၀ US$
Beta
၁.၅၈
Shares outstanding
၁၃.၄၂ ကုဋေ
No. of employees
၂ ထောင်
Open
၁၆၂.၂၉ US$
High
၁၇၀.၅၀ US$
Low
၁၆၂.၀၀ US$
Mkt. cap
ဋေ ၂.၂၇ ထ
Avg. vol.
၁.၇၈ သန်း
Volume
၆.၆၁ သိန်း
52-wk high
၁၉၁.၀၅ US$
52-wk low
၆၆.၅၉ US$
EPS
-၃.၅၀ US$
Beta
၁.၅၈
Shares outstanding
၁၃.၄၂ ကုဋေ
No. of employees
၂ ထောင်
News stories
From web sources and news partners
Zacks
Zacks
·
ပြီးခဲ့သည့် ၁ နာရီ
Natera Partners With TransCode to Advance Colorectal Cancer Trial
Stock Titan
Stock Titan
·
ပြီးခဲ့သည့် ၁ ရက်
Five short talks will explore blood-based cancer tests at ESMO, among 25 studies from Guardant and collaborators.
MarketBeat
MarketBeat
·
ပြီးခဲ့သည့် ၂ ရက်
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
Profile
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers. Wikipedia
About Guardant Health Inc
CEOHelmy Eltoukhy | AmirAli Talasaz
Employees၂.၅ ထောင်
Founded၂၀၁၂
HeadquartersPalo Alto, ကယ်လီဖိုးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
SectorHealth care provider
Websiteguardanthealth.com
Analyst ratings
Based on 19 analysts giving stock ratings to GH in the past 3 months
Strong buy
Buy
19
Hold
0
Sell
0
12-month forecast
Based on 19 Wall Street analysts offering 12 month price targets for GH in the last 3 months.
Highest
Current ၁၆၉.၂၅ US$
၂၂၅.၀၀ US$ (+၃၂.၉၄%)
Average
၂၀၃.၂၉ US$ (+၂၀.၁၁%)
Lowest
၁၈၀.၀၀ US$ (+၆.၃၅%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kallum Titchmarsh
Morgan Stanley
Buy
Maintained
၂၀၀.၀၀ US$
+၁၈.၂%
10/20/2026
Eve Burstein
Bernstein
Buy
Reiterated
၂၁၀.၀၀ US$
+၂၄.၁%
10/19/2026
Casey Woodring
J.P. Morgan
Buy
Maintained
၁၉၅.၀၀ US$
+၁၅.၂%
10/14/2026
Lu Li
Bank of America Securities
Buy
Maintained
၂၀၀.၀၀ US$
+၁၈.၂%
10/09/2026
Michael Ryskin
Bank of America Securities
Buy
Maintained
၂၀၀.၀၀ US$
+၁၈.၂%
10/09/2026
Luke Sergott
Barclays
Buy
Maintained
၂၂၀.၀၀ US$
+၃၀%
10/07/2026
Subbu Nambi
Guggenheim
Buy
Maintained
၂၀၀.၀၀ US$
+၁၈.၂%
10/01/2026
Evie Koslosky
Goldman Sachs
Buy
Maintained
၂၂၅.၀၀ US$
+၃၂.၉%
09/20/2026
William Bonello
Craig-Hallum
Buy
Maintained
-
-
09/15/2026
David Westenberg
Piper Sandler
Buy
Maintained
၁၉၃.၀၀ US$
+၁၄%
09/15/2026
Unknown Analyst
UBS
Buy
Maintained
၂၂၅.၀၀ US$
+၃၂.၉%
09/09/2026
Doug Schenkel
UBS
Buy
Maintained
၂၂၅.၀၀ US$
+၃၂.၉%
09/09/2026
Jamie Clark
Rothschild & Co Redburn
Buy
Initiated
၂၀၃.၀၀ US$
+၁၉.၉%
09/08/2026
Matt Larew
William Blair
Buy
Maintained
-
-
09/08/2026
Mark Massaro
BTIG
Buy
Reiterated
၁၉၅.၀၀ US$
+၁၅.၂%
09/01/2026
Bradley Bowers
Mizuho Securities
Buy
Maintained
၂၀၀.၀၀ US$
+၁၈.၂%
08/04/2026
Mason Carrico
Stephens
Buy
Maintained
၁၉၅.၀၀ US$
+၁၅.၂%
08/04/2026
Kyle Mikson CFA
Canaccord Genuity
Buy
Maintained
၂၀၅.၀၀ US$
+၂၁.၁%
08/02/2026
Daniel Arias
Stifel Nicolaus
Buy
Maintained
၁၈၀.၀၀ US$
+၆.၄%
08/03/2026
Dan Leonard
RBC Capital
Buy
Reiterated
၂၀၀.၀၀ US$
+၁၈.၂%
07/31/2026
Daniel Brennan
TD Cowen
Buy
Reiterated
၂၁၀.၀၀ US$
+၂၄.၁%
07/31/2026
Brandon Couillard
Wells Fargo
Buy
Maintained
၁၂၅.၀၀ US$
-၂၆.၁%
07/29/2026
Patrick B Donnelly
Citi
Buy
Maintained
၂၁၅.၀၀ US$
+၂၇%
07/08/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
၂၀၀.၀၀ US$
+၁၈.၂%
07/06/2026
Puneet Souda
Leerink Partners
Buy
Reiterated
-
-
06/02/2026
Paige Chamberlain‏
Wolfe Research
Buy
Reiterated
၁၅၀.၀၀ US$
-၁၁.၄%
06/01/2026
Unknown Analyst
Wolfe Research
Buy
Reiterated
၁၅၀.၀၀ US$
-၁၁.၄%
06/01/2026
Andrew Brackmann
William Blair
Buy
Maintained
-
-
05/27/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
၁၂၉.၀၀ US$
-၂၃.၈%
05/08/2026
Andrew Cooper
Raymond James
Buy
Reiterated
၁၂၉.၀၀ US$
-၂၃.၈%
02/23/2026
Last report
၂၀၂၆ ဇူ ၃၀
Fiscal period
Q2 2026
-၀.၄၂ US$ / -၀.၃၉ US$
-၇.၈၁%miss
Revenue / Est. (USD)
၃၃.၅၀ ကုဋေ / ၃၁.၄၄ ကုဋေ
+၆.၅၃%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၂၆.၅၂ ကုဋေ
၂၈.၁၃ ကုဋေ
၃၀.၁၇ ကုဋေ
၃၃.၅၀ ကုဋေ
Cost of goods sold
၉.၃၆ ကုဋေ
၉.၉၅ ကုဋေ
၁၀.၄၉ ကုဋေ
၁၁.၅၉ ကုဋေ
Cost of revenue
၉.၃၆ ကုဋေ
၉.၉၅ ကုဋေ
၁၀.၄၉ ကုဋေ
၁၁.၅၉ ကုဋေ
Research and development expenses
၉.၀၀ ကုဋေ
၉.၈၃ ကုဋေ
၉.၁၀ ကုဋေ
၉.၆၅ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၁၈.၀၅ ကုဋေ
၂၀.၄၂ ကုဋေ
၂၂.၇၁ ကုဋေ
၂၅.၀၆ ကုဋေ
Operating expense
၂၇.၀၅ ကုဋေ
၃၀.၂၅ ကုဋေ
၃၁.၈၁ ကုဋေ
၃၄.၇၁ ကုဋေ
Total operating expenses
၃၆.၄၁ ကုဋေ
၄၀.၂၀ ကုဋေ
၄၂.၃၀ ကုဋေ
၄၆.၃၁ ကုဋေ
Operating income
-၉.၈၉ ကုဋေ
-၁၂.၀၇ ကုဋေ
-၁၂.၁၄ ကုဋေ
-၁၂.၈၁ ကုဋေ
Other non operating income
-၄.၈၀ သောင်း
-၄.၆၉ သန်း
၁.၅၅ သန်း
၃.၀၈ သိန်း
EBT including unusual items
-၉.၂၆ ကုဋေ
-၁၃.၀၂ ကုဋေ
-၁၁.၁၇ ကုဋေ
-၁၂.၀၀ ကုဋေ
EBT excluding unusual items
-၉.၂၅ ကုဋေ
-၁၁.၆၅ ကုဋေ
-၁၁.၁၇ ကုဋေ
-၁၁.၉၀ ကုဋေ
Income tax expense
၁.၃၆ သိန်း
-၁.၇၃ သန်း
၃.၇၂ သိန်း
၁.၈၅ သိန်း
Effective tax rate
-၀.၁၅%
၁.၃၃%
-၀.၃၃%
-၀.၁၅%
Other operating expenses
-
-
-
-
Net income
-၉.၂၇ ကုဋေ
-၁၂.၈၅ ကုဋေ
-၁၁.၂၁ ကုဋေ
-၁၂.၀၁ ကုဋေ
Net profit margin
-၃၄.၉၆%
-၄၅.၆၈%
-၃၇.၁၅%
-၃၅.၈၇%
Earnings per share
-၀.၃၉
-၀.၅၀
-၀.၄၅
-၀.၄၂
Interest and investment income
၇.၃၉ သန်း
၁.၀၀ ကုဋေ
၁.၁၂ ကုဋေ
၁.၀၂ ကုဋေ
Interest expense
-၉.၄၃ သိန်း
-၁.၁၈ သန်း
-၃.၀၅ သန်း
-၁.၃၅ သန်း
Net interest expenses
၆.၄၅ သန်း
၈.၈၅ သန်း
၈.၁၀ သန်း
၈.၈၅ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၈.၉၅ ကုဋေ
-၁၁.၀၆ ကုဋေ
-၁၁.၁၉ ကုဋေ
-၁၁.၈၆ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google အက်ပ်များ